Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX versus LODINE.
ANAPROX vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category C
Category C
NSAID
NSAID